Oculis Holding AG (OCS) Retained Earnings (2021 - 2026)
Oculis Holding AG (OCS) posted quarterly Retained Earnings of -$527.9 million for Q1 2026, down 48.88% year-over-year from -$1.0 billion in Q1 2025, and down 9.72% quarter-over-quarter from -$481.1 million in Q4 2025.
Oculis Holding AG (OCS) Retained Earnings (2021 - 2026) Analysis & Trends
Oculis Holding AG's Retained Earnings history runs 6 years deep, the most recent figure standing at -$527.9 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 48.88% year-over-year to -$527.9 million; the TTM figure through Mar 2026 stood at -$527.9 million (down 48.88% YoY), while the FY2025 annual figure was -$463.8 million, down 42.88% from the prior year.
- Retained Earnings for Q1 2026 stood at -$527.9 million, down from -$481.1 million in the prior quarter.
- The five-year high for Retained Earnings was -$115.2 million in Q4 2022, with the low at -$527.9 million in Q1 2026.
- The 5-year median for Retained Earnings is -$296.5 million (2024), against an average of -$315.6 million.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings sank 95.51% in 2023, then sank 38.55% in 2024.
- Oculis Holding AG's Retained Earnings stood at -$115.2 million in 2022, then slumped by 95.51% to -$225.2 million in 2023, then plunged by 44.73% to -$326.0 million in 2024, then plunged by 47.59% to -$481.1 million in 2025, then declined by 9.72% to -$527.9 million in 2026.
- Business Quant data shows OCS's Retained Earnings at -$527.9 million in Q1 2026, -$481.1 million in Q4 2025, and -$451.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | -535.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -535.62 Mn |
| Mar 31, 2026 | -527.87 Mn |
| Dec 31, 2025 | -481.09 Mn |
| Sep 30, 2025 | -451.29 Mn |
| Jun 30, 2025 | -415.69 Mn |
| Mar 31, 2025 | -354.55 Mn |
| Dec 31, 2024 | -325.97 Mn |
| Sep 30, 2024 | -296.52 Mn |
| Jun 30, 2024 | -261.75 Mn |
| Mar 31, 2024 | -247.32 Mn |
| Dec 31, 2023 | -225.22 Mn |
| Sep 30, 2023 | -212.03 Mn |
| Jun 30, 2023 | -188.93 Mn |
| Dec 31, 2022 | -115.20 Mn |
| Dec 31, 2021 | -78.39 Mn |